Sökning: onr:"swepub:oai:DiVA.org:uu-498884" >
Survival by First-l...
Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients : A National Population-based Study in Sweden
-
- Weibull, Caroline E. (författare)
- Karolinska Institutet
-
- Wasterlid, Tove (författare)
- Karolinska Institutet
-
- Wahlin, Bjorn Engelbrekt (författare)
- Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.;Karolinska Inst, Dept Med Huddinge, Unit Hematol, Stockholm, Sweden.
-
visa fler...
-
- Andersson, Per-Ola (författare)
- Sahlgrens Univ Hosp, Sect Hematol & Coagulat, Gothenburg, Sweden.
-
- Ekberg, Sara (författare)
- Karolinska Institutet
-
- Lockmer, Sandra (författare)
- Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.;Karolinska Inst, Dept Med Huddinge, Unit Hematol, Stockholm, Sweden.
-
- Enblad, Gunilla (författare)
- Uppsala universitet,Institutionen för immunologi, genetik och patologi
-
- Crowther, Michael J. (författare)
- Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.;Red Door Analyt, Stockholm, Sweden.
-
- Kimby, Eva (författare)
- Karolinska Institutet
-
- Smedby, Karin E. (författare)
- Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden.;Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.
-
visa färre...
-
Karolinska Institutet Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden;Karolinska Inst, Dept Med Huddinge, Unit Hematol, Stockholm, Sweden. (creator_code:org_t)
- Wolters Kluwer, 2023
- 2023
- Engelska.
-
Ingår i: HemaSphere. - : Wolters Kluwer. - 2572-9241. ; 7:3
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- In follicular lymphoma (FL), progression of disease <= 24 months (POD24) has emerged as an important prognostic marker for overall survival (OS). We aimed to investigate survival more broadly by timing of progression and treatment in a national population-based setting. We identified 948 stage II-IV indolent FL patients in the Swedish Lymphoma Register diagnosed 2007-2014 who received first-line systemic therapy, followed through 2020. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated by first POD at any time during follow-up using Cox regression. OS was predicted by POD using an illness-death model. During a median follow-up of 6.1 years (IQR: 3.5-8.4), 414 patients experienced POD (44%), of which 270 (65%) occurred <= 24 months. POD was represented by a transformation in 15% of cases. Compared to progression-free patients, POD increased all-cause mortality across treatments, but less so among patients treated with rituximab(R)-single (HR = 4.54, 95% CI: 2.76-7.47) than R-chemotherapy (HR = 8.17, 95% CI: 6.09-10.94). The effect of POD was similar following R-CHOP (HR = 8.97, 95% CI: 6.14-13.10) and BR (HR = 10.29, 95% CI: 5.60-18.91). The negative impact of POD on survival remained for progressions up to 5 years after R-chemotherapy, but was restricted to 2 years after R-single. After R-chemotherapy, the 5-year OS conditional on POD occurring at 12, 24, and 60 months was 34%, 46%, and 57% respectively, versus 78%, 82%, and 83% if progression-free. To conclude, POD before but also beyond 24 months is associated with worse survival, illustrating the need for individualized management for optimal care of FL patients.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Weibull, Carolin ...
-
Wasterlid, Tove
-
Wahlin, Bjorn En ...
-
Andersson, Per-O ...
-
Ekberg, Sara
-
Lockmer, Sandra
-
visa fler...
-
Enblad, Gunilla
-
Crowther, Michae ...
-
Kimby, Eva
-
Smedby, Karin E.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
HemaSphere
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet